Navigation Links
Study Demonstrates the Anti-Inflammatory Properties of Pine Bark Extract on Inflammatory Mediators COX-2 and 5-LOX
Date:7/14/2009

HOBOKEN, N.J., July 15 /PRNewswire/ -- A recent study published in "International Immunopharmacology," reveals why Pycnogenol(R) (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, is effective for reducing inflammation and soothing pain associated with various health problems. Dr. Raffaella Canali of the National Research Institute on Food and Nutrition in Rome, Italy, found that Pycnogenol(R) inhibits the generation of COX-2 and 5-LOX, two naturally occurring enzymes associated with a host of inflammatory conditions.

"This study reveals that Pycnogenol can actually decrease pain and reduce inflammatory conditions, as has been previously reported, by shutting down the production of specific enzymes involved with inflammation," said Dr. Canali.

Inflammation is a tightly controlled, concerted action of immune cells fighting infections, irritations and injuries. When inflammation goes out of control it may target the body's own tissue such as in arthritis or asthma. The worst known cases are the auto-immune diseases.

The study investigated healthy volunteers ranging from ages 35-50, who consumed Pycnogenol(R) tablets (150 mg) for five consecutive days in the morning before breakfast. Blood was drawn before and after supplementation to investigate how immune cells respond towards pro-inflammatory stimuli. The behavior of specific white blood cells (leukocytes) for generating a repertoire of enzymes in inflammatory condition was tested by real-time PCR. The gene expression of enzymes COX-2, 5-LOX, FLAP and COX-1 were monitored and the products these enzymes generate, prostaglandins and leukotrienes, were quantified.

A baseline study revealed that the volunteers' immune cells rapidly initiated production of COX-2, 5-LOX and FLAP enzymes upon pro-inflammatory stimulation. Taking Pycnogenol(R) almost entirely subdued COX-2, 5-LOX and FLAP induction in the immune cells of volunteers. Control studies showed that Pycnogenol(R) did not have an effect on generation of the COX-1 enzyme, thus the potential for typical NSAID side effects is defied. While Pycnogenol(R) is not a COX-2-specific inhibitor; it blocks the COX-2 enzyme production during inflammation only. There are COX-2 enzymes not involved in inflammation in other organs such as the kidneys, where it has important physiologic functions.

"Standard NSAID medications reduce the production of prostaglandins by COX enzymes for lowering the pain," explains Dr. Canali. "In contrast, Pycnogenol(R) turns to the root of the problem, completely stopping the production of COX-2 in inflammation. Thus far, Pycnogenol(R) seems to be a unique tool for modulating inflammatory processes."

These pharmacologic findings are consistent with past clinical trials of Pycnogenol(R) that showed significantly lowered leukotriene levels in asthmatic patients, a condition originating from 5-LOX. Three recent clinical trials also showed pain relief and a reduced need for pain medication in arthritis patients after taking Pycnogenol(R), results that are linked to COX-2 inhibition. One arthritis study showed a significant reduction of inflammatory marker C-reactive protein. Pycnogenol(R) has been shown to inhibit inflammation in several dysmenorrhoea studies and also a reduction in skin inflammation related to sunburn and acne.

About Pycnogenol(R)

Pycnogenol(R) is a natural plant extract originating from the bark of the maritime pine that grows along the coast of southwest France and is found to contain a unique combination of procyanidins, bioflavonoids and organic acids, which offer extensive natural health benefits. The extract has been widely studied for the past 40 years and has more than 220 published studies and review articles ensuring safety and efficacy as an ingredient. Today, Pycnogenol(R) is available in more than 700 dietary supplements, multi-vitamins and health products worldwide. For more information, visit www.pycnogenol.com.

Natural Health Science Inc. (NHS), based in Hoboken, New Jersey, is the North American distributor for Pycnogenol(R) (pic-noj-en-all) brand French maritime pine bark extract on behalf of Horphag Research. Pycnogenol(R) is a registered trademark of Horphag Research Ltd., Guernsey, and its applications are protected by U.S. patents #5,720,956 / #6,372,266 and other international patents. Horphag Research Ltd. is the recipient of the 2008 Frost & Sullivan North American Health Ingredients Excellence in Research Award. NHS has the exclusive rights to market and sell Pycnogenol(R) in North America and benefits from more than 40 years of scientific research assuring the safety and efficacy of Pycnogenol(R) as a dietary supplement. For more information about Pycnogenol(R) visit our Web site at www.pycnogenol.com.


'/>"/>
SOURCE Natural Health Science Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Study finds survival rates from gastrointestinal tumors improving among African-Americans
2. Mayo Clinic study continues to refine most effective methods to predict Alzheimers disease
3. Mayo Clinic Study Continues to Refine Most Effective Methods to Predict Alzheimers Disease
4. Reminder program dramatically increases mammography rates, Kaiser Permanente study finds
5. FAIR CEO Blasts Kaiser Foundation & Public Agenda HIV/AIDS Study Results as "Absolute Nonsense"
6. Reminder Program Dramatically Increases Mammography Rates, Kaiser Permanente Study Finds
7. Study estimates radiation dose, cancer risk from coronary artery calcium screening
8. Fluorescent probes may permit monitoring of chemotherapy effectiveness, Stanford study shows
9. Queens University study aims at early diagnosis for ADHD and Parkinsons disease
10. Cats Purrfect at Getting Needs Met, Study Shows
11. Study Evaluating Efficacy and Safety of Two Low-dose Regimens of PREMARIN Vaginal Cream for the Treatment of Moderate to Severe Vaginal Atrophy Now Published
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
Breaking Medicine Technology: